On April 7th, the Hainan Boao Lecheng International Medical Tourism Pilot Zone Management Bureau signed a strategic cooperation agreement with the Haikou National High tech Industry Development Zone Management Committee and Kangzhe Pharmaceutical Holdings Co., Ltd. The three parties will conduct comprehensive and deepening strategic cooperation on the "Lecheng Introduction Haikou Production" of Kangzhe Pharmaceutical's international innovative pharmaceutical equipment varieties.
Ni Qiang, Deputy Governor of Hainan Province and Director of the Free Trade Port Office of the Provincial Party Committee, Liu Liwu, Director of the Hainan Provincial Department of Industry and Information Technology, Jia Ning, Director of the Hainan Provincial Medical Insurance Bureau and Lecheng Management Bureau, Zhu Ning, Director of the Hainan Provincial Drug Administration Bureau, Deng Lishong, Member of the Standing Committee and Vice Mayor of Haikou Municipal Party Committee, Feng Guang, Deputy Director of the Haikou National High tech Zone Management Committee, Fu Zhu, Deputy Director of Lecheng Management Bureau, and Lin Gang, Chairman and CEO of Kangzhe Pharmaceutical, Executive Director and Chief Financial Officer Chen Yanling and others attended the signing ceremony.
It is understood that Kangzhe Pharmaceutical is an open platform enterprise that links pharmaceutical innovation and commercialization, controls product lifecycle management, and is committed to providing competitive products and services. After this cooperation is reached, an innovative drug of Kangzhe Pharmaceutical dermatology will be used through Lecheng. After it is quickly registered and listed through Lecheng's real research channel, it will be produced in Haikou National High tech Zone. It is expected to become the second international innovative drug to be launched in Haikou through "Lecheng Introduction Haikou Production", following the case of Pioneer's Traxil for Injection.
Lecheng Management Bureau and Kangzheweisheng have reached strategic cooperation to jointly create a product innovation and transformation center
On April 6th, Mr. Lin Gang, Chairman, CEO, and President of Kangzhe Pharmaceutical, as well as Ms. Chen Yanling, Executive Director, Chief Financial Officer, and Vice President of Kangzhe Pharmaceutical, visited the Lecheng Pilot Area for investigation and research. They visited Boao Super Hospital, First Age Life Care Center, Ruijin Hainan Medical Hospital, and the "Never Ending" International Innovation Medicine Exhibition, and held a signing ceremony with the Lecheng Management Bureau.
At the symposium, Lecheng Management Bureau signed a cooperation agreement with Kangzhe Weisheng Technology Development Co., Ltd. (hereinafter referred to as "Kangzhe Weisheng"), a subsidiary of Kangzhe Pharmaceutical Holdings Co., Ltd. Kangzheweisheng (including its proposed Hainan subsidiary) and Lecheng Management Bureau will fully utilize the advantages of the Lecheng Pilot Zone's pilot policy, effectively leverage the driving role of both parties in professional fields, jointly create a product innovation and transformation center, and accelerate the research and development and transformation of medical technology innovation achievements in the field of ophthalmology.
According to the agreement, Lecheng Management Bureau and Kangzheweisheng will carry out in-depth cooperation in areas such as entering the Lecheng Medical Industry Transformation Platform, cooperation between government, industry, university, research and medical research, academic exchange and training, joint talent cultivation, and joint construction of innovation and transformation centers, jointly promoting the acceleration of research and development transformation of medical technology innovation achievements in the field of ophthalmology, and accelerating the industrialization and marketization of medical technology innovation achievements.
Jia Ning, Director of Lecheng Management Bureau, stated that after rapid development in recent years, the Lecheng Pilot Zone has moved from a "policy highland" to a "platform highland", gathering multiple industrial resources such as academician and expert teams, medical institutions, and pharmaceutical enterprises. The Lecheng Medical Industry Transformation Platform is the first medical technology innovation public platform in Lecheng, aimed at solving clinical needs, product technology transformation, and industrialization issues. I am very pleased to see leading pharmaceutical companies like Kangzhe Pharmaceutical participate in the construction of the platform. I look forward to conducting comprehensive and multi-level cooperation between both parties to do a good job in the research and development and transformation of innovative products, and incubating more cutting-edge scientific and technological innovation achievements in the field of ophthalmology.
Lin Gang, Chairman and CEO of Kangzhe Pharmaceutical, stated that Kangzhe Pharmaceutical is an open platform enterprise that links pharmaceutical innovation and commercialization, controls product lifecycle management, and is committed to providing competitive products and services to meet unmet medical needs. Kangzhe Pharmaceutical has laid out 30 differentiated innovation pipelines worldwide, mainly focused on Global First (FIC) and Best in Class (BIC). We hope that through this comprehensive cooperation with Lecheng Pilot Zone, Kangzhe Pharmaceutical can quickly introduce more global new products and technologies in the field of ophthalmology to China, continuously provide patients with more high-quality medical products, contribute greater value to society, and assist in the construction of a healthy China.
Wu Huabing, President of Haikou National High tech Zone International Investment Consulting Co., Ltd., participated in the symposium. Wang Linlang, General Manager of Kangzhe Weisheng, Huang Anjun, General Manager of Kangzhe Meili, Zongfang, Deputy General Manager of Kangzhe Meili, Wu Yong, Deputy General Manager of Shanghai Carnation, Zhu Hongtao, Director of Kangzhe Pharmaceutical's Pharmaceutical Manufacturing Department, Wu Sanyan, Director of Kangzhe Pharmaceutical's Legal Department, Cao Yang, Director of Kangzhe Pharmaceutical's Administrative Management Department, and Kang Luqi, Director of Kangzhe Pharmaceutical's President Office, participated in the research activity.